BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Boosts Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 61.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 67,891 shares of the medical equipment provider’s stock after purchasing an additional 25,714 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Intuitive Surgical were worth $30,201,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. Capital World Investors boosted its holdings in Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after purchasing an additional 73,634 shares during the last quarter. Edgewood Management LLC boosted its holdings in Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in Intuitive Surgical by 4.6% in the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock worth $1,791,253,000 after purchasing an additional 198,483 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the transaction, the insider now directly owns 295 shares of the company’s stock, valued at $145,113.45. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,120 shares of company stock valued at $25,528,753. Corporate insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ISRG shares. Morgan Stanley raised their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Stifel Nicolaus increased their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research report on Friday, July 19th. The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. JPMorgan Chase & Co. increased their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Finally, BTIG Research increased their price target on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Performance

ISRG opened at $489.07 on Tuesday. The stock has a market capitalization of $173.47 billion, a price-to-earnings ratio of 88.28, a PEG ratio of 5.41 and a beta of 1.39. The company has a fifty day moving average of $469.05 and a 200 day moving average of $426.06. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period last year, the company posted $1.18 earnings per share. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.